- Home
- COYA vs ADAG Comparison
COYA vs ADAG Comparison
Compare COYA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- ADAG
- Stock Information
- Founded
- COYA 2020
- ADAG 2011
- Country
- COYA United States
- ADAG China
- Employees
- COYA N/A
- ADAG N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- ADAG Health Care
- Exchange
- COYA Nasdaq
- ADAG Nasdaq
- Market Cap
- COYA 99.8M
- ADAG 90.8M
- IPO Year
- COYA 2022
- ADAG 2021
- Fundamental
- Price
- COYA $6.67
- ADAG $1.99
- Analyst Decision
- COYA Strong Buy
- ADAG Strong Buy
- Analyst Count
- COYA 4
- ADAG 1
- Target Price
- COYA $16.50
- ADAG $8.00
- AVG Volume (30 Days)
- COYA 88.2K
- ADAG 121.4K
- Earning Date
- COYA 08-11-2025
- ADAG 08-05-2025
- Dividend Yield
- COYA N/A
- ADAG N/A
- EPS Growth
- COYA N/A
- ADAG N/A
- EPS
- COYA N/A
- ADAG N/A
- Revenue
- COYA $3,685,107.00
- ADAG $103,204.00
- Revenue This Year
- COYA $21.49
- ADAG $6,488.89
- Revenue Next Year
- COYA N/A
- ADAG $57.50
- P/E Ratio
- COYA N/A
- ADAG N/A
- Revenue Growth
- COYA N/A
- ADAG N/A
- 52 Week Low
- COYA $4.65
- ADAG $1.33
- 52 Week High
- COYA $10.24
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- COYA 65.20
- ADAG 55.18
- Support Level
- COYA $5.66
- ADAG $1.60
- Resistance Level
- COYA $6.07
- ADAG $1.96
- Average True Range (ATR)
- COYA 0.32
- ADAG 0.17
- MACD
- COYA 0.06
- ADAG 0.01
- Stochastic Oscillator
- COYA 88.60
- ADAG 84.78
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.